Beijing Centergate Technologies (holding) Co., Ltd. engages in the pharmaceutical industry in China and internationally. The company offers Anemarrhena saponin BII and capsules for vascular dementia treatment; Bifonazole API, an opioid receptor antagonist; Naloxone Hydrochloride injection to relieve acute ethanol poisoning; Naltrexone Hydrochloride tablets to block the pharmacological effects of exogenous opioids; Hydrocodone acetaminophen tablets for the treatment of moderate to severe pain; Ambroxol Hydrochloride injection for acute and chronic lung diseases; Tramadol Hydrochloride injection for moderate to severe pain; Febuxostat tablets for long-term treatment of hyperuricemia; and Glipizide Dispersible tablets to improve glycemic control in adults with type 2 diabetes. It also provides Metoprolol succinate API for hypertension and coronary heart disease; Bisoprolol Fumarate tablets for chronic stable heart failure; Tropisetron Mesylate injection for prevention and treatment of nausea and vomiting; Cediodine lozenges used for chronic pharyngitis; Phencynonate Hydrochloride tablets used to prevent motion sickness; Oxycodone Hydrochloride injection, an analgesic; Bifonazole cream used to treat various fungal skin diseases; Huperzine A to improve memory impairment; Wujia Biochemical capsule for vaginal bleeding caused by qi deficiency and blood stasis; Lactobacillus tablets used for abnormal intestinal fermentation; Tramadol Hydrochloride tablets for the treatment of pain in adults; Aminophene Tramadol tablets for treatment of moderate to severe acute pain; Clindamycin phosphate vaginal gel used to treat bacterial vaginosis; and Benidipine Hydrochloride tablets for essential hypertension and angina pectoris. Beijing Centergate Technologies (holding) Co., Ltd. was founded in 1999 and is based in Beijing, China.
Metrics to compare | 000931 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship000931PeersSector | |
---|---|---|---|---|
P/E Ratio | 74.9x | 10.3x | 9.1x | |
PEG Ratio | 5.34 | −0.04 | 0.01 | |
Price/Book | 2.7x | 0.7x | 0.9x | |
Price / LTM Sales | 1.7x | 0.6x | 3.9x | |
Upside (Analyst Target) | - | 12.3% | 13.5% | |
Fair Value Upside | Unlock | −0.2% | 0.4% | Unlock |